Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating today.

Tyler Van Buren has given his Buy rating due to a combination of factors including the promising performance of Arcellx Inc’s Anito-cel, which is considered best-in-class based on current data. The anticipated mid-year update for the iM-1 study is expected to align with previous positive results, and the company is on track for a 2026 launch in the 4L+ setting, with the BLA filing approaching.
Additionally, the iMMagine-1 study presented impressive topline data at ASH 2024, demonstrating high overall response rates and competitive metrics compared to similar studies. The absence of significant toxicities in the Anito-cel trials further supports the positive outlook, with the company maintaining its timeline for future developments and launches.